

PRODUCT INFORMATION



SRT 3025 (hydrochloride)

Item No. 34420

CAS Registry No.: 2070015-26-6
Formal Name: 5-(3-methoxypropyl)-2-phenyl-N-[2-[6-(1-pyrrolidinylmethyl)thiazolo[5,4-b]pyridin-2-yl]phenyl]-4-thiazolecarboxamide, monohydrochloride

MF: C₃₁H₃₁N₅O₂S₂ • HCl

FW: 606.2


Purity: ≥98%

UV/Vis.: λ_{max}: 231, 281, 353 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SRT 3025 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the SRT 3025 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. SRT 3025 (hydrochloride) is soluble in the organic solvent chloroform at a concentration of approximately 30 mg/ml. SRT 3025 (hydrochloride) is slightly soluble in ethanol, DMSO, and dimethyl formamide.

Description

SRT 3025 is an activator of sirtuin 1 (SIRT1).¹⁻³ It increases SIRT1 levels in, and inhibits RANKL-induced osteoclastogenesis of, mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 2 μM.¹ SRT 3025 inhibits the proliferation of SU.86.86 pancreatic adenocarcinoma cells (IC₅₀ = 0.98 μM).² It decreases plasma levels of LDL, VLDL, and total cholesterol in *ApoE*^{-/-} mice fed a high-cholesterol diet when administered at a dose of 3.18 g/kg.³

References

1. Gurt, I., Artsi, H., Cohen-Kfir, E., *et al.* The Sirt1 activators SRT2183 and SRT3025 Inhibit RANKL-induced osteoclastogenesis in bone marrow-derived macrophages and down-regulate Sirt3 in *Sirt1* null cells. *PLoS One* **10**(7), e0134391 (2015).
2. Chini, C.C.S., Espindola-Netto, J.M., Mondal, G., *et al.* SIRT1-activating compounds (STAC) negatively regulate pancreatic cancer cell growth and viability through a SIRT1 lysosomal-dependent pathway. *Clin. Cancer Res.* **22**(10), 2496-507 (2015).
3. Miranda, M.X., van Tits, L.J., Lohmann, C., *et al.* The Sirt1 activator SRT3025 provides atheroprotection in *ApoE*^{-/-} mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. *Eur. Heart J.* **36**(1), 51-59 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM